MRVI•Maravai LifeSciences reported year-to-date 2026 revenue of $163.1 million, up 20%, with adjusted EBITDA of $34.8 million and an adjusted gross margin of 61.1%. Cost reductions under its corporate realignment plan exceeded $65 million.
Maravai LifeSciences reported year-to-date 2026 revenue of $163.1 million, up 20%, in an investor presentation. Adjusted EBITDA was $34.8 million and adjusted gross margin was 61.1%. TriLink base revenue rose 13% year over year, driven by mRNA growth, while Cygnus revenue increased 4% for its sixth consecutive quarterly gain. Cost reductions under the corporate realignment plan exceeded $65 million, surpassing the initial target of more than $50 million.
